Cardiometabolic diseases, including cardiovascular conditions, type 2 diabetes, and obesity, are increasing globally, straining healthcare systems and escalating costs. Traditional one-size-fits-all drug therapies lack patient-centricity and fail to address individual variability, highlighting the need for affordable, accessible treatments. However, questions arise:

  • How Is Patient-Centric Care Evolving?

Patient-centric care is now integrating nutritional, behavioral, and drug therapies, with a shift towards precision health using genome-wide association studies to identify gene-drug interactions. Life science companies are intensifying omics-based research and forming strategic partnerships to develop effective pharmacological and digital therapies.

  • What Role Do Digital and AI-Based Therapies Play?

Combining digital therapeutics, artificial intelligence (AI)-based diagnostics, and behavioral therapies with traditional treatments is crucial for managing cardiometabolic diseases. The convergence of biopharma, digital therapeutics, medical devices, and health technology is enhancing patient care, improving outcomes, and reducing costs.

  • Why Is Adopting Integrated Care Models Essential?

As cardiometabolic cases continue to rise, adopting integrated care models that leverage adjunct therapies is essential. Here, we explore best practices in precision cardiometabolic care, highlight companies excelling in this field, and identify growth opportunities, providing insights for enhancing patient outreach and addressing access challenges.

What Is the Impact of Precision Interventions on Cardiometabolic Diseases? Is Your Team Poised to Capitalize on the New Growth Opportunities?

Cardiometabolic diseases encompass conditions like obesity, diabetes, and cardiovascular diseases (CVDs), including coronary artery diseases (CADs) and chronic heart failure. Precision interventions are targeting the root causes, aiming to enhance health outcomes, prevent complications, and lower the burden of care. These approaches, spanning discovery, diagnostics, treatment, and monitoring, are depending on individual profiles, covering genetics, metabolism, and the gut microbiome. This personalized approach is transforming healthcare by addressing individual variability and promoting more targeted interventions.

What Are Some of the Emerging Best Practices in Precision Cardiometabolic Care?

  • Integrated Care Model – The growing demand for coordinated virtual/home-based care is paving the way for integrated care delivery models. Multi-disciplinary teams, including

cardiologists, endocrinologists, dietitians, and psychologists, are collaborating to create personalized and preventative care protocols.

Companies to Action

Vida Health’s team of human coaches, licensed therapists, and health experts are offering transformative care for patients with cardiometabolic diseases through mobile apps, coaching, therapy, medication, and remote monitoring.

  • Rise of Cardiometabolic Medicine The higher prevalence of cardiometabolic conditions is increasing focus on a new medicine subspecialty, cardiometabolic medicine. This field is stimulating insulin secretion, inhibiting glucagon secretion, slowing gastric emptying, increasing urinary glucose excretion, and modulating renal function.

Companies to Action

Microbiota modulation therapies (probiotics/prebiotics) are emerging as new treatment options for glucose metabolism and insulin sensitivity in type II diabetes.

  • Growing Adoption of DTxDigital therapeutics (DTx) catering to the entire cardiometabolic spectrum are seeing higher adoption rates than single disease-focused solutions. Predictive and monitoring solutions are gaining acceptance among healthcare providers and patients and are garnering reimbursements from payors.

Companies to Action

  • Liva Healthcare’s platform is addressing the entire cardiometabolic spectrum rather than focusing on a single disease.
  • Omada Health’s solutions are enabling informed decision-making for dose optimization, reduction of unnecessary medication use, and episodic risk management, which are directly impacting chronic care costs and are seeing increased adoption.

To learn more about these best practices and discover growth opportunities, check out our latest analysis in “Global Precision Cardiometabolic Growth Opportunities” by clicking here.

About Frost & Sullivan:

Frost & Sullivan, the growth pipeline company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Pipeline as a Service provides the CEO’s Growth Team with transformational strategies and best-practice models to drive the generation, evaluation, and implementation of powerful growth opportunities. Let us coach you on your transformational journey, while we actively support you in fostering collaborative initiatives within your industry’s ecosystem. Our transformation journey is fueled by four powerful components, ensuring your success in navigating the ever-changing landscape of your industry.

  • Schedule a complementary Growth Dialog with our team to dive deeper into transformational strategies and explore specific needs within your company.
  • Become a Frost Growth Expert in your area of specialization and share your expertise and passion with the community through our think tanks.
  • Join Frost & Sullivan’s Growth Council and become an integral member of a dynamic community focused on identifying growth opportunities and addressing critical challenges that influence your industry.
  • Designate your company as a Companies to Action to increase exposure to investors, new M&A opportunities, and other growth prospects for your business.
Your Transformational Growth Journey Starts Here

Share This